Investors
Invest in the category of one.
Every aesthetic category has a manufacturer, except autologous fat transfer. Etienna is building the first, and raising a Series Seed to complete IND-enabling studies and meet with the FDA.
The raise
Series Seed
$5 to 10 million
The market
$1.1 – 2.5B
U.S. fat transfer
The platform
ETB-001
Autologous; licensed from UMass Chan
First in human
2028
Lead indication: hand
Investor deck
Request access
Tell us a little about yourself and we'll unlock the deck right away.